Literature DB >> 16278038

Immunological responses after immunisation of mice with microparticles containing antigen and single stranded RNA (polyuridylic acid).

Angie Westwood1, Stephen J Elvin, Gareth D Healey, E Diane Williamson, Jim E Eyles.   

Abstract

Certain toll-like receptor (TLR) agonists, e.g. CpG DNA, can be used as potent vaccine 'adjuvants'. It is known that some sequences of single stranded (ss) RNA stimulate proinflammatory and antiviral responses following interaction with TLR 7 and 8. We have encapsulated ovalbumin (OVA) in the presence and absence of polyuridylic acid (poly-U) inside polylactide microparticles. In comparison to microparticles containing only OVA, bulk cultures of bone marrow-derived plasmacytoid and myeloid dendritic cells produced more (P<0.05) IL-12 and interferon (IFN)-alpha when stimulated with microparticles containing OVA and poly-U. Subcutaneous injection of comicroencapsulated OVA and poly-U resulted in statistically elevated levels of serum anti-OVA IgG1 (P<0.05 versus naïve mice). Conversely, anti-OVA IgG1 levels in C57 BL6 mice immunised with OVA loaded microparticles (without RNA) were statistically indifferent to naïve animals. Furthermore, injection of coencapsulated OVA and poly-U resulted in (P<0.05) greater numbers of OVA specific IFN-gamma secreting T-cells as compared with mice injected with OVA loaded microparticles. A similar trend was seen in mice immunised with OVA loaded microparticles decorated with CpG or solutions of admixed OVA and CpG (P<0.05). These data demonstrate, for the first time, that appropriately formulated ssRNA can act as a potent adjuvant and modulator of adaptive immunological responses.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16278038     DOI: 10.1016/j.vaccine.2005.10.021

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  9 in total

1.  The Yersinia enterocolitica invasin protein promotes major histocompatibility complex class I- and class II-restricted T-cell responses.

Authors:  O T Bühler; C A Wiedig; Y Schmid; G A Grassl; E Bohn; I B Autenrieth
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

2.  A novel high-throughput cell-based method for integrated quantification of type I interferons and in vitro screening of immunostimulatory RNA drug delivery.

Authors:  David N Nguyen; Phillip Kim; Luis Martínez-Sobrido; Brett Beitzel; Adolfo García-Sastre; Robert Langer; Daniel G Anderson
Journal:  Biotechnol Bioeng       Date:  2009-07-01       Impact factor: 4.530

3.  Tunable degradation of acetalated dextran microparticles enables controlled vaccine adjuvant and antigen delivery to modulate adaptive immune responses.

Authors:  Naihan Chen; Monica M Johnson; Michael A Collier; Matthew D Gallovic; Eric M Bachelder; Kristy M Ainslie
Journal:  J Control Release       Date:  2018-02-02       Impact factor: 9.776

Review 4.  Toll or toll-free adjuvant path toward the optimal vaccine development.

Authors:  Ken J Ishii; Shizuo Akira
Journal:  J Clin Immunol       Date:  2007-03-17       Impact factor: 8.317

5.  The 3' CCACCA sequence of tRNAAla(UGC) is the motif that is important in inducing Th1-like immune response, and this motif can be recognized by Toll-like receptor 3.

Authors:  Zhijun Wang; Li Xiang; Junjie Shao; Zhenghong Yuan
Journal:  Clin Vaccine Immunol       Date:  2006-07

6.  Interferon-alpha and viral triggers promote functional maturation of human monocyte-derived dendritic cells.

Authors:  A Farkas; G Tonel; F O Nestle
Journal:  Br J Dermatol       Date:  2008-03-25       Impact factor: 9.302

7.  Molecular Dynamics Studies of Poly(Lactic Acid) Nanoparticles and Their Interactions with Vitamin E and TLR Agonists Pam1CSK4 and Pam3CSK4.

Authors:  Simon Megy; Stephanie Aguero; David Da Costa; Myriam Lamrayah; Morgane Berthet; Charlotte Primard; Bernard Verrier; Raphael Terreux
Journal:  Nanomaterials (Basel)       Date:  2020-11-05       Impact factor: 5.076

8.  Antigen delivery by lipid-enveloped PLGA microparticle vaccines mediated by in situ vesicle shedding.

Authors:  Melissa C Hanson; Anna Bershteyn; Monica P Crespo; Darrell J Irvine
Journal:  Biomacromolecules       Date:  2014-06-16       Impact factor: 6.988

Review 9.  Biodegradable Polymeric Nanoparticles-Based Vaccine Adjuvants for Lymph Nodes Targeting.

Authors:  Alice Gutjahr; Capucine Phelip; Anne-Line Coolen; Claire Monge; Anne-Sophie Boisgard; Stéphane Paul; Bernard Verrier
Journal:  Vaccines (Basel)       Date:  2016-10-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.